Page 124 - 南京医科大学自然版

第44卷第7期
·1008 · 南 京 医 科 大 学 学 报 2024年7月

Two single⁃arm，multicenter phase⁃II trials of PD⁃1 inhibi⁃ durvalumab and tremelimumab in pulmonary sarcomatoid
tors in patients with pulmonary sarcomatoid carcinoma carcinoma：KCSG⁃LU16⁃07［J］. Thorac Cancer，2020，11
（NCCH1603/NCCH1703）［J］. Ann Oncol，2021，32： （12）：3482-3489
S1002-S1003 ［48］DAFNI U，TSOURTI Z，VERVITA K，et al. Immune
［36］ LEE J，CHOI Y，JUNG H A，et al. Outstanding clinical checkpoint inhibitors，alone or in combination with che⁃
efficacy of PD⁃1/PD⁃L1 inhibitors for pulmonary pleomor⁃ motherapy，as first⁃line treatment for advanced non⁃small
phic carcinoma［J］. Eur J Cancer，2020，132：150-158 cell lung cancer. A systematic review and network meta⁃
［37］DOMBLIDES C，LEROY K，MONNET I，et al. Efficacy of analysis［J］. Lung Cancer，2019，134：127-140
immune checkpoint inhibitors in lung sarcomatoid carci⁃ ［49］ GU L，WEI X，ZHANG Z，et al. Treatment response to
noma［J］. J Thorac Oncol，2020，15（5）：860-866 immunotherapy after crizotinib resistance in a patient
［38］DOMBLIDES C，MONNET I，MAZIERES J，et al. Efficacy with pulmonary sarcomatoid carcinoma harboring MET
of immune checkpoint inhibitors in lung sarcomatoid car⁃ exon 14 skipping mutation：a case report［J］. Clin Med
cinoma：data from a French multicentric cohort［EB/OL］. Insights Oncol，2022，16：1353188145
［2018- 10- 30］. http：//www.annalsofoncology.org/article/ ［50］ MAYENGA M，ASSIÉ J B，MONNET I，et al. Durable
S0923⁃7534（19）495-99-9/pdf responses to immunotherapy of non ⁃ small cell lung
［39］BABACAN N A，PINA I B，SIGNORELLI D，et al. Rela⁃ cancers harboring MET exon ⁃ 14 ⁃ skipping mutation：a
tionship between programmed death receptor ⁃ ligand 1 series of 6 cases［J］. Lung Cancer，2020，150：21-25
expression and response to checkpoint inhibitor immuno⁃ ［51］丁雨薇，翁姗姗，王永辉，等. 信迪利单抗联合小剂量化
therapy in pulmonary sarcomatoid carcinoma：a pooled 疗有效控制肺肉瘤样癌1例［J］. 实用肿瘤杂志，2022，
analysis［J］. Clin Lung Cancer，2020，21（5）：e456-e463 37（4）：363-366
［40］ROESEL C，KAMBARTEL K，KOPEIKA U，et al. Lazarus⁃ ［52］TANIGUCHI H，TAKEMOTO S，OZASA M，et al. Re⁃
type tumour response to therapy with nivolumab for sarco⁃ markable response to pembrolizumab with platinum ⁃
matoid carcinomas of the lung［J］. Curr Oncol，2019，26 doublet in PD⁃L1⁃low pulmonary sarcomatoid carcinoma：
（2）：e270-e273 a case report［J］. Thorac Cancer，2021，12（7）：1126-1130
［41］XU L，TAO N N，LIANG B，et al. Use of PD⁃1 inhibitor ［53］KONG F，WANG W，GONG L，et al. Anti⁃PD⁃1 antibody
tislelizumab in the treatment of advanced pulmonary sar⁃ camrelizumab plus doxorubicin showed durable response
comatoid carcinoma：a case report［J］. Thorac Cancer， in pulmonary sarcomatoid carcinoma：case report and
2022，13（3）：502-505 literature review［J］. J Clin Pharm Ther，2020，45（6）：
［42］PLANCHARD D，REINMUTH N，ORLOV S，et al. ARC⁃ 1489-1496
TIC：durvalumab with or without tremelimumab as third⁃ ［54］GUO M N，JALIL A，LIU J Y，et al. Tongue swelling as a
line or later treatment of metastatic non⁃small⁃cell lung manifestation of tongue metastasis from pulmonary sarco⁃
cancer［J］. Ann Oncol，2020，31（5）：609-618 matoid carcinoma：a case report［J］. World J Clin Oncol，
［43］BRAHMER J R，LEE J S，CIULEANU T E，et al. Five⁃ 2021，12（4）：282-289
year survival outcomes with nivolumab plus ipilimumab ［55］JIN C，YANG B. Dramatic response of pulmonary sarco⁃
versus chemotherapy as first⁃line treatment for metastatic matoid carcinoma to nivolumab combined with anlotinib：
non⁃small⁃cell lung cancer in CheckMate 227［J］. J Clin a case report［J］. Case Rep Oncol，2020，13（2）：601-605
Oncol，2023，41（6）：1200-1212 ［56］DAI G，HE L，YAN Q，et al. Case report：advanced pulmo⁃
［44］WEI S C，ANANG N，SHARMA R，et al. Combination anti⁃ nary sarcomatoid carcinoma with adrenal gland metastasis
CTLA⁃4 plus anti⁃PD⁃1 checkpoint blockade utilizes cel⁃ after sintilimab combined with anlotinib treatment［J］.
lular mechanisms partially distinct from monotherapies［J］. Front Oncol，2023，13：1167516
Proc Natl Acad Sci USA，2019，116（45）：22699-22709 ［57］YI X，XU W，TANG G，et al. Individual risk and prognos⁃
［45］ALIFU M，TAO M，CHEN X，et al. Checkpoint inhibitors tic value prediction by machine learning for distant metas⁃
as dual immunotherapy in advanced non⁃small cell lung tasis in pulmonary sarcomatoid carcinoma：a large cohort
cancer：a meta ⁃ analysis［J］. Front Oncol，2023，13： study based on the SEER database and the Chinese popu⁃
1146905 lation［J］. Front Oncol，2023，13：1105224
［46］许杨悦，胡 蒙，武常玲，等. 真实世界中肺癌免疫检查 ［58］LIANG X，CHENG Y，YUAN Z，et al. Clinical，pathologi⁃
点抑制剂治疗的安全性及有效性［J］. 南京医科大学学 cal and treatment factors associated with the survival of
报（自然科学版），2023，43（12）：1668-1674 patients with pulmonary sarcomatoid carcinoma［J］. On⁃
［47］KIM M，KEAM B，OCK C Y，et al. Phase II study of col Lett，2020，19（6）：4031-4039